-
Trypsin BA5744 for Reliable Cell Assays
2026-08-15
Learn how Trypsin, SKU BA5744, can improve consistency in cell detachment, viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects formulation, preparation, controls, and interpretation with practical laboratory decision-making.
-
Q7j and HER2–EMT Targeting in Breast Cancer
2026-08-14
The reference study used a Mubritinib-derived scaffold to synthesize 32 novel HER-2 inhibitors and identified Q7j as a promising compound against HER-2-positive breast cancer models. Its significance lies in linking HER-2 signaling pathway inhibition with reduced migration and EMT-associated protein changes, while also showing stronger activity than Mubritinib in an SKBR3 orthotopic xenograft model.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows
2026-08-14
Y-27632 dihydrochloride provides a practical way to tune Rho–ROCK signaling during stem-cell handling, cytoskeletal assays, and invasion models. This guide translates the reference study’s neural-grafting insights into controlled ex vivo workflows while separating validated findings from optimization recommendations.
-
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-08-13
The reference study introduces a phenotypic small-molecule screening strategy to reduce SPP1 expression in tumor-associated macrophages and packages lead compounds in a TAM-avid CANDI nanoconstruct. Its lead compound, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions across murine models, supporting macrophage-state modulation as a therapeutic strategy.
-
Natural Compounds Against SARS-CoV-2: Docking Insights
2026-08-13
The reference study used virtual screening, molecular docking, and molecular dynamics to evaluate vitamins against two SARS-CoV-2 vulnerabilities: the spike receptor-binding domain and the 3CL protease. Its results nominate overlapping and target-specific compounds for follow-up antiviral therapeutics research, while also illustrating why computational binding predictions require biochemical and cellular validation.
-
EGF-Driven Migration Without EMT in A549 Cells
2026-08-12
The reference study shows that EGF stimulates migration of A549 lung adenocarcinoma cells without inducing the epithelial–mesenchymal transition or increasing invasion. By comparing EGF, TGFβ, and combined treatment with imaging, functional, molecular, and proteomic assays, the authors distinguish motility from invasive progression and identify different pathway dependencies.
-
Cisplatin (CDDP) Workflow for Cancer Research
2026-08-12
Build more reproducible Cisplatin experiments by linking DNA crosslinking, ROS, apoptosis, and resistance phenotypes in one workflow. This guide translates clinical combination-therapy logic into practical cell-based, mechanistic, and xenograft assay choices while addressing formulation and readout failures.
-
MG-262: Proteasome Inhibition Meets Cell Fate
2026-08-11
MG-262 and Z-Leu-Leu-Leu-B(OH)2 provide a reversible, cell-permeable route to interrogate proteasome-dependent protein quality control. This article connects proteasome inhibition assays with BIRC2/BIRC3 inflammatory signaling, helping researchers distinguish direct proteostasis effects from downstream apoptosis and cell-cycle phenotypes.
-
SP600125 in ROS–MAPK Pain Signaling
2026-08-11
Explore how SP600125, a selective JNK inhibitor, can dissect the ROS–MAPK–Panx3 axis implicated in orofacial neuropathic pain. This article translates recent trigeminal ganglion findings into a rigorous assay strategy while separating evidence from proposed applications.
-
Ionophore Toxicity in Animals: Molecular Insights
2026-08-10
Ekinci, Chłodowska, and Olejnik integrate clinical reports with cellular and molecular evidence to explain how polyether ionophores injure cardiac and skeletal muscle. Their review emphasizes species, age, dose, and tiamulin co-exposure as critical determinants of risk, while identifying disrupted ion homeostasis and mitochondrial oxidative phosphorylation as central mechanistic themes.
-
CHIR-99021 (CT99021) for Reliable Cell Assays
2026-08-09
Learn how CHIR-99021 (CT99021), SKU A3011, can help laboratories separate true changes in cell state from solvent, timing, and assay-readout artifacts. This scenario-based guide covers mechanism, compatibility, protocol control, data interpretation, and practical vendor selection.
-
Lactate–GPR81/FARP1 Drives Insulin-Independent Uptake
2026-08-08
The 2026 Cell Research study identifies L-lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81–FARP1–RAC1 pathway that promotes GLUT4 translocation. Its genetic, pharmacological, physiological, and human genetic evidence positions lactate sensing as a potential complement to insulin-based control of hyperglycemia.
-
Cell lysis buffer for WB and IP in PCa
2026-08-07
A practical guide to using a non-denaturing lysis system for Western blotting, immunoprecipitation, and co-IP in prostate cancer microenvironment studies. The workflow separates cell-pellet extraction from conditioned-medium assays, helping preserve phosphorylation, protein abundance, and native ANGPTL4–IQGAP1 interactions.
-
Neuroligin 1, Striatal D2 Neurons, and PKC in Repetitive Beh
2026-08-07
This study uncovers how Neuroligin 1 deficiency in striatal D2-expressing medium spiny neurons drives autistic-like repetitive behaviors via PKC overactivation. The findings clarify cellular and molecular links between synaptic adhesion molecules, striatal circuitry, and behavioral phenotypes, informing mechanistic and pharmacological strategies for ASD research.
-
Neuroligin 1 Proteolysis Sustains Social Memory via Cofilin
2026-08-06
Liu et al. (2025) reveal that social interactions trigger α- and γ-secretase-mediated proteolysis of neuroligin 1 in the ventral hippocampus, producing a peptide fragment (NLG1-CTD) essential for maintaining social memory. Their work identifies the NLG1-CTD/cofilin signaling axis as a central mechanism linking synaptic plasticity to memory retention, with implications for neuropsychiatric research.